CHARLENE VIERS: Open Payments
NPI 1750774782 · BLACKSBURG, VA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$999 in 33 payments from 19 companies in 2025. Trend: 2023 $1,550 · 2024 $2,599 · 2025 $999
Food & beverage: $665Long term medical supply or device loan: $333
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation | 6 | $397 |
| Merck Sharp & Dohme LLC | 4 | $93 |
| Incyte Corporation | 3 | $54 |
| PFIZER INC. | 2 | $53 |
| GlaxoSmithKline, LLC. | 2 | $53 |
| E.R. Squibb & Sons, L.L.C. | 2 | $44 |
| Bayer Healthcare Pharmaceuticals Inc. | 2 | $42 |
| Genentech USA, Inc. | 1 | $30 |
| Ipsen Biopharmaceuticals, Inc | 1 | $27 |
| Deciphera Pharmaceuticals Inc. | 1 | $26 |
Products named: KISQALI, KEYTRUDA, IBRANCE, ZEJULA, Itovebi, LUTATHERA, Onivyde, QINLOCK.
Industry payments across VA — which companies pay providers there.
